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Chapter 1 
Introduction 
 Description of the problem. Attention deficit hyperactivity disorder (ADHD) is one of 
the most common mental health disorders in the United States. ADHD is typically diagnosed in 
childhood between the ages of 4 and 7. According to a 2011 United States survey by the Centers 
for Disease Control (CDC), ADHD effects 11% of children ages 4-17, and that number has risen 
an average 5% per year since 2003. The worldwide prevalence of ADHD in children is 5.29%, 
demonstrating a much higher incidence in the United States. The hallmark findings of ADHD are 
inattention, impulsiveness, and hyperactivity which lead to difficulty completing tasks, following 
directions, and getting along with others. If left untreated, these behaviors can significantly 
hinder the child’s performance in school and his or her ability to be successful later in life. For 
this reason, clinicians frequently prescribe stimulant medications which are considered first line 
therapy for ADHD with or without cognitive behavioral therapy (CBT). According to the same 
2011 survey, 69% of children diagnosed with ADHD were medicated for their condition. This 
equates to 6.1% of all children ages 4-17 in the United States. Evidence suggests that despite 
being a ‘diagnosis of childhood’, many patients with ADHD benefit from medication therapy 
into adulthood. Adult patients who were not diagnosed during childhood, but demonstrate 
ADHD behaviors may also benefit from initiation of stimulant therapy. This data demonstrates 
the need for healthcare providers to have a clear understanding of the effects of long term 
stimulant therapy when prescribing them for their patients. 
 Stimulant medications include methylphenidate, dextroamphetamine, and amphetamines. 
Common brand names include Adderall, Ritalin, Concerta, and Vyvanse. These drugs are 
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regulated by the drug enforcement administration (DEA) and are considered schedule II drugs. 
Schedule II drugs have a high potential for abuse and abuse of the drug may lead to 
psychological or physical dependence. The United States food and drug administration (FDA) 
mandates a black box warning on stimulant medications related to abuse potential and risk for 
cardiovascular adverse events and sudden death. This information alone raises the question: are 
these medications appropriate for children? In addition to the high potential for abuse, stimulants 
carry a side effect profile that includes depression, hypertension, stoke, sudden death, 
cardiomyopathy, growth suppression, insomnia, and anorexia. Despite these risks, stimulant 
medications are considered relatively safe and effective therapy for control of ADHD in children 
and adolescents. However, as the incidence of ADHD rises, practitioners are likely to see more 
patients on stimulant therapy well into adulthood. The purpose of this literature review is to 
determine the effects associated with long term use of stimulant medications for ADHD and how 
these effects, positive and negative, may influence future practice guidelines.  
 Definition of terms.   
 Conceptual terms. ADHD is defined by the DSM-V criteria as a persistent pattern of 
inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In 
order to satisfy the diagnosis of ADHD several associated behaviors must be present for a 
prescribed period of time. This literature review favors studies regarding ADHD that adhere to 
this diagnostic standard. Stimulant medications refer to medications that stimulate the central 
nervous system and produce a sympathomimetic effect. For the purposes of this literature review 
the term stimulant refers specifically to the class of stimulants called the phenethylamines which 
is the parent class of methylphenidate and amphetamine medications. Side effects are effects that 
occur secondary to the primary goal of the therapy and are usually undesirable.  
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 Operational terms. Operationally, stimulant medication refers to a group of medications 
designed to enhance wakefulness, alertness, attentiveness, as well as boost motivation and 
productivity. For the purposes of this literature review the term stimulant is inclusive of multiple 
unique ADHD medications including but not limited to amphetamines (Adderall), 
methylphenidate (Ritalin), and Lisdexamfetamine (Vyvanse). With respect to ADHD 
medication, the known side effects are related to stimulant medication’s effects on 
neurotransmitters, and the sympathetic nervous system. For this review the operational definition 
of side effects was comprised from the most commonly investigated secondary effects associated 
with stimulant therapy. The side effects are sudden death, substance abuse, and other 
cardiovascular risk. Other cardiovascular risk may be further defined/measured as increased 
incidence of tachycardia, hypertension, electrocardiogram changes, and development of 
cardiomyopathy. When discussing long-term effects of stimulant medications long term therapy 
refers to any therapy lasting greater than 6 months, or long-term therapy as defined by the 
individual study criteria. Therapy may be initiated in childhood or adulthood. Because ADHD 
medications are typically prescribed on a long term basis the discussion of the effects of these 
medications is in reference to long term therapy unless otherwise specified.  
 Theoretical framework. 
 For the purpose of this literature review, the effects of long term use of stimulant 
medications are discussed in respect to Becker’s health belief model. This theoretical framework 
assumes that patient’s attitudes and actions towards health behavior are determined by four 
points; the severity of the potential illness, the susceptibility to that illness, the benefits of taking 
action, and perceived barriers to that action (Janz & Becker, 1984). ADHD is considered a 
neuro-cognitive disorder and as such the outcomes of treatment can be measured subjectively by 
EFFECTS OF STIMULANT MEDICATIONS FOR ADHD 5 
 
the patient’s perception of effectiveness of treatment. These outcomes may also be evident in 
quantitative values such as test scores. This model was originally designed to examine patient’s 
attitudes towards preventative health behavior. It may be adapted to the use of pharmacological 
interventions because the discussion of the long-term effects of stimulant medications plays a 
large role in determining the perceived benefits and barriers.  Also, because of the variation in 
long-term ADHD prognosis, patients and providers may individualize their treatment goals based 
on the risks and long-term effects associated with stimulant medications. The patient’s perceived 
severity of their ADHD and their attitudes toward stimulant medications will be augmented by 
the barriers to the intervention (medication side effects and cost) or lack of perceived benefits 
(low efficacy).  This risk versus benefit analysis of treatment options falls squarely within the 
realm of Becker’s health belief model.  
 PICO question 
 In patients with attention deficit hyperactivity disorder (ADHD) what are the effects 
associated with long-term use of stimulant medications? Stimulant medications have other on-
label uses for conditions such as narcolepsy, binge eating disorder, and obsessive compulsive 
disorder. For the purposes of this literature review, the population is limited to those patients 
taking these medications for ADHD. The intervention of interest is the stimulant drug itself as 
compared to other therapy which includes non-stimulant medications and cognitive behavioral 
therapies, and no therapy. Alternate therapies will not be examined to determine superiority; 
rather date will be generated regarding the effects associated with one intervention so that 
consumers and health care providers may make informed decisions about their treatment options.  
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Chapter Two 
Literature Review 
 Articles for this literature review were selected after careful review of the CINAHL and 
Medline databases as well as the clinical key database accessed through the McKee Library.  An 
important eligibility criterion was that the article had been published in the last 5 years.  
Literature older than five years may be included if the study was considered a landmark study or 
contributed to current guidelines. The article must address ADHD independently and not 
concurrent to any comorbid conditions such as autism, Tourette’s, or other developmental 
disorders. The article must discuss use of stimulant medications for the treatment of ADHD. 
Articles discussing side-effects of non-prescription stimulant use and or abuse were not included. 
Articles that addressed adult ADHD treatment and outcomes were sought out to determine the 
efficacy of stimulant therapy beyond childhood. Key words used were: attention deficit 
hyperactivity disorder (ADHD), stimulant(s), side-effects, cardiac, substance abuse, adult, and 
long-term effects. For the purposes of this review specific attention was paid to studies that 
examined cardiac risk factors, risk of sudden-death, substance abuse, and psychosocial 
outcomes. Because of the wide age range of patients diagnosed and prescribed stimulant 
medications this review included studies that addressed both pediatric and adult populations.  
A search of the databases using the search term ADHD with Boolean (and) terms 
stimulant medication and side effects yielded a total of 459 articles published in English since 
2010 with full text available.  A portion of these articles were duplicates available in more than 
one database. Many of these articles were comparison studies demonstrating the efficacy or 
superiority of one stimulant versus another. These articles were not included in the literature 
review. This left approximately 80 articles that were eligible for the literature review including 
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primary research studies, case-control studies, systematic reviews, and current literature reviews. 
These results were narrowed down to 20 articles based on their attention to the concepts of 
interest; substance abuse, cardiac side effects, and adult ADHD.  
Presentation of Literature 
 Eight of the 20 studies addressed cardiovascular implications, 7 addressed adult ADHD 
considerations specifically, and 4 addressed substance abuse outcomes. One study combined the 
concepts of interest and reported on psychosocial adversity and mortality in adults with 
childhood ADHD. Cardiovascular and substance abuse articles included childhood, adolescent, 
and adult population studies. 
Stimulant Medication and Cardiac Side Effects 
 Cardiovascular side effects are considered to be one of the primary concerns of clinicians 
who prescribe stimulant medications.  This is due to varied reports regarding increased incidence 
of sudden death during stimulant therapy, and FDA advisory committee warnings regarding the 
safety of stimulant use in children. However, these reports have not been substantiated by current 
literature. Current evidence based guidelines indicate stimulants as first-line therapy for ADHD. 
The literature demonstrates a steady increase in the incidence of ADHD as well as an increase in 
the utilization of stimulant medications for its treatment. Multiple large studies have been 
conducted to investigate cardiac risk factors associated with stimulant use including elevated 
heart rate, elevated blood pressure, and ECG changes. These factors are thought to have 
cumulative effects on cardiovascular health over-time. Therefore, they may be predictive of 
long-term adverse effects such as acute myocardial infarction, stroke, and sudden death. 
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 Elevation in heart rate was frequently observed during initiation of stimulant therapy 
(within 90 minutes of administration) in children but had no statistically significant impact with 
data endpoints from 5 weeks to 6 months (Awudu & Besag, 2014).  In sample populations of 
adults taking stimulant medications for ADHD, small elevations (4-10 bpm) in heart rate were 
documented throughout the course of the study. This resulted in a persistent but stable elevation 
in heart rate up to the endpoint of 2 years (Hammerness, Surman, & Chilton, 2011). A multi-age, 
multi-population study by Martinez-Raga, Knecht, Szerman, and Martinez (2013) similarly 
found marginal but statistically significant elevation in heart rate and systolic blood pressure 
within the first 90 minutes of stimulant administration to children. In adults, similar elevations in 
heart rate and systolic blood pressure were identified at multiple data endpoints from 6 weeks to 
3 years. None of the studies examined dose-dependent relationships among stimulant medication 
and elevation of heart rate and/or blood pressure. Each of the studies accounted for standard 
dosing of the medication. No differences in outcomes were demonstrated in populations taking 
methylphenidate versus amphetamines. Three of the 8 studies discussing cardiovascular risk 
examined ECG changes as a primary outcome. None of the studies recorded any evidence that 
use of stimulant medications caused ECG changes, specifically QT elongation, at data points up 
to 6 months (Awudu & Besag, 2014), (Martinez-rage et al., 2013), (Hammerness et al., 2011).  
 Risk of sudden death was a unique outcome evaluated independent of heart and blood 
pressure in two of the studies (Winterstein et al., 2012), (McCarthy, Cranswick, Potts, Taylor, & 
Wong, 2009).  Both of these studies were large population-based retrospective cohort studies. 
They included massive sample groups which were representative of the general population with 
ADHD. Neither study demonstrated an increased incidence of sudden death among patients with 
ADHD who were taking stimulant medication. Data from these studies did not report the length 
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of time the patient had been taking stimulants, so it is difficult to say if long-term use of 
stimulants may influence this outcome. With such large population studies it is difficult to 
account for covariates such as medication dose, type, and duration. However, it is reasonable to 
assume that the study durations of 7 and 9 years respectively would have captured any sudden 
deaths linked to intermediate use of stimulant medications. McCarthy et al. incidentally found an 
increased rate of suicide among the population of patients with ADHD compared to the general 
population. It is not known if suicidality is associated with the impulsivity associated with 
ADHD or is a side effect of medications. This study demonstrates the need for further research to 
determine the relationship between suicide and ADHD. 
 Cardiovascular complaints are among the most common subjective complaints reported 
by stimulant medication users. They include palpitations and fatigue. Since the aforementioned 
studies demonstrated very little quantitative evidence regarding stimulant mediation and 
cardiovascular demands, additional studies were reviewed to investigate this phenomenon. Kelly 
et al. (2014) examined cardiac autonomic dysfunction and arterial stiffness related to stimulant 
medication use in children to explore how increased sympathetic stimulation affects cardiac 
automaticity and vascular health. In a sample of 138 children, specialized measures were used to 
determine heart rate variability and pulse wave velocity (arterial stiffness). The results were 
adjusted for sex, race, and tanner stage and divided into affected and control groups. The results 
demonstrated increased heart rate variability in subjects taking stimulant medication for ADHD.  
The level of variability was on par with children affected by type 1 diabetes and childhood 
obesity. They also demonstrated increased arterial stiffness in the ADHD population. The mean 
duration of stimulant use was 2.79 years. There was no identifiable relationship between duration 
of stimulant therapy and/or dose of stimulant therapy related to hemodynamic values. This study 
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identified two subclinical effects of increased sympathetic tone which are known independent 
risk factors for cardiovascular disease. The short term nature of this study makes it difficult to 
assess the impact of these effects over time. These findings generate a research question to 
determine the long-term implications of stimulant therapy and increased sympathetic tone.  
The body’s response to catecholamines impacts our energy level, wakefulness, and 
experience of fatigue. In children taking stimulant medications, these effects have been blunted 
in response to exercise. Mahon, Woodruff, Horn, Marjerrison, and Cole (2012) conducted a 
small volunteer based study to assess how stimulant medications affect heart rate and perceived 
exertion. They determined that children taking stimulant medications for ADHD were likely to 
report lower than average levels of exertion at a given heart rate. Furthermore, heart rates of 
children taking stimulant medications were higher than controls at the same perceived level of 
exertion. The findings of this study cannot be generalized due to the small sample size; however 
they do provide a possible understanding of the patient’s experience of palpitations and fatigue. 
The researchers in this study were conducting their research as part of a larger investigation into 
how exercise may help decrease side effects and improve motor skills in children with ADHD. 
The reporters may be biased in their interpretation of the data based on their investment in the 
outcomes of the larger study.  
Substance Abuse 
 Two of the 4 substance abuse articles were large population based studies using national 
registry data. One was a smaller community sample, and the fourth was a review of current 
literature. The two large population based studies demonstrated an increased occurrence of 
substance abuse as defined by DSM-IV criteria in patients with a diagnosis of ADHD. Of the 
large studies, one contained follow-up up to 15 years, while the other ended at four years. The 
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four-year study targeted a previously determined high risk age group at a mean age of 16.4 years. 
Not only were children with ADHD more likely to develop a substance use disorder, they had a 
younger age of first substance use, and nicotine dependence than controls. This study did not 
investigate how stimulant medication for ADHD influenced ADHD symptoms or propensity for 
substance use disorders (Groenman et al. 2013). The second study by Chang et al. (2014) 
examined rates of substance abuse among patients with ADHD based on current, former, or 
never use of stimulant medications. Because of their access to prescription databases they were 
also able to trend duration of therapy and correlate periods of non-use with other records 
including criminal convictions or hospital visits. Results were published controlling for age, sex, 
and medication status in 2009 (the data point of interest). Their results demonstrated that 
stimulant medications did not increase the incidence of substance abuse in patients with ADHD. 
Furthermore, there was a protective effect of stimulant medication where there was an inverse 
relationship between duration of stimulant therapy and rate of substance abuse. These findings 
are useful to practice because of the large sample size and the comparison of the intervention 
within the ADHD population versus the general population. Data is limited because of the severe 
nature of the substance abuse cases identified by criminal or hospital data. Less severe cases of 
substance abuse may be under-represented resulting in skewed data. Further controlled trials 
would be ideal to collect more sensitive reliable data, however conducting such a study would be 
unethical. 
 The review of literature and the small community based study supported the previous 
research stating that 1) A diagnosis of ADHD in childhood is associated with an increased risk 
for substance abuse and nicotine dependence. 2) The use of stimulant medications in childhood 
is not associated with increased long-term risk of substance abuse. The literature review posits 
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that current evidence is support enough for providers to feel comfortable in prescribing stimulant 
medications for ADHD so long as there is appropriate assessment of substance abuse behaviors, 
consistent follow-up, and education about the course of therapy (Nelson, & Galon, 2012). 
Winters et al. (2011) pose a more interesting theory based on their findings suggesting that the 
protective benefit of stimulant medication for ADHD with respect to substance abuse are not 
carried forth past adolescence. Therefore, adults who are prescribed stimulant medications may 
represent a unique subset when it comes to propensity for substance abuse. This theory requires 
further research to determine outcomes in this specific population.  
Adult ADHD 
 ADHD is no longer a diagnosis of childhood. Its effects including inattention and 
impulsivity have far reaching consequences if not adequately addressed in childhood. Research 
suggests that primary care provider’s attitudes towards adult ADHD impact their ability and 
willingness to prescribe both stimulant and non-stimulant therapies. Even in the absence of 
negative views of adult ADHD only 57.5% of providers in a small convenience sample were 
confident in treating adult ADHD (Martinson & Tang, 2010).  Two studies examined quality of 
life measures in adults with ADHD. A systematic review of literature looked at the metrics used 
to determine quality of life in adults with ADHD and how ADHD symptoms impacted these 
scores. The use of established validated tools for measuring quality of life make the results of 
this review significant in terms of providing quantitative and reliable data. According to 
Agarwal, Goldenberg, Perry, and Ishak (2012), adults with ADHD demonstrate lower overall 
quality of life scores than the general population. Furthermore, they experience anxiety, 
depression, and daytime sleepiness more commonly than non-ADHD adults. Other significant 
areas of dissatisfaction included decreased emotional control for women, and decreased social 
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functioning in men.  Specific treatment goals would require individualized assessment of barriers 
to optimum functional status. However, multiple studies reported that the use of stimulant 
therapy improved vitality, social, emotional, and physical well-being after 10 weeks of treatment. 
These findings suggest that treating ADHD itself decreased the prevalence of comorbid 
psychological conditions and improves overall quality of life. 
 Outcomes affecting quality of life include occupational success, economic stability, 
educational attainment, and marital history. These elements significantly influence lifelong social 
functioning and success. For this reason, Klein et al. (2012) examined the relationship between 
childhood ADHD and adult functional status. A prospective study followed 135 Caucasian males 
with ADHD from childhood and compared them to a demographically similar control group. 
They found that adults who suffered from ADHD in childhood received 2.5 years less education, 
and had lower levels of occupational achievement. These two outcomes produced an 
understandably lower socioeconomic status. Similar to the study by Agarwal et al. (2012) the 
population with childhood ADHD had higher rates of adult substance abuse and nicotine 
dependence that the general population. Klein et al. suggested that their findings indicated the 
importance of treatment of childhood ADHD. However, because their study did not examine 
outcomes based on treatment, further studies are required before specific recommendations can 
be made. Pitts, Mangle, and Asherson (2015) further quantified these findings using an ADHD 
impairment and symptoms scale which was completed by a sample of 210 adults (mean age 32). 
Similarly, the results showed greater difficulties in social functioning, personal relationships, 
personal finances, mood/temper control, self-organization, and planning, and rule breaking 
behavior among the population with ADHD.  
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 ADHD can have devastating effects on adult functional status. Two of the studies 
investigated ADHD in older adults (>50) to grasp the full spectrum of impairment caused by 
adult ADHD. Brod, Schmitt, Goodwin, Hodgkins, and Niebler (2011) conducted interviews to 
collect data from 24 adult patients with ADHD, average age 66. None of the patients were 
diagnoses with ADHD in childhood, and all were diagnosed at age 30 or greater. Participants 
voiced impairment with managing finances, including inadequate retirement funds, as well as 
difficulty maintaining relationships with family and friends. The quality of life score for older 
adults with ADHD demonstrated the greatest discrepancy in perception of life productivity. 
Surprisingly, 79% of the participants were currently taking ADHD medication. They reported 
improved focus and attention since being on the medication. The researchers believe this small 
pilot study highlights the value of diagnosing and treating ADHD in patients of every age. These 
findings are obviously limited by sample size and largely qualitative nature of data collection. 
Lensing, Zeiner, Sandvik, and Opjorsmoen (2015) specifically studied pharmacology for ADHD 
in the older adult, mean age 55.8. Surprisingly, 87.9% of the sample (N=149) reported treatment 
for ADHD. Of the 95 currently receiving treatment, 87 were taking a stimulant medication. The 
treated population demonstrated better attention and better employment outcomes than those 
who were not treated. Those who continued their treatment reported greater self-efficacy than 
those who did not. The researchers identify their sample population as a potential weakness 
because it was compiled from the national ADHD patient organization. The sample relies on 
self-reporting and may not be an adequate representation of the general population with ADHD. 
The findings indicate the tolerability and efficacy of stimulant medications into late-adulthood. 
In the future, large population based studies would be useful to create generalizable findings and 
treatment recommendations.  
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Chapter 3 
Discussion and Synthesis 
 This review of literature has several applications for advanced practice. First, the use of 
stimulant medications is not associated with adverse cardiovascular side-effects or risk of sudden 
death. Despite the black box warnings, stimulant medications can be considered safe for use in 
children and adults. Therefore, practitioners should feel comfortable and confident prescribing 
them for their patients with ADHD. The findings regarding substance abuse indicate a need for 
practitioners to educate patients and parents about high risk behaviors and vulnerability in this 
population. Furthermore, they should be vigilant in their patient care and insure regular patient 
follow-up throughout the course of therapy for appropriate monitoring. Finally, practitioners 
need to be aware of their own attitudes regarding adult ADHD and recognize the long-term 
implications if it is left untreated. Practitioners should continue to educate themselves about 
treatment options, and should refer patients to specialists when needed.  
 Current research regarding cardiovascular safety includes many large population-based 
studies and long-term follow-up. Despite the strength of these studies, stimulant medications still 
carry a black box warning for sudden death. Providers and policy makers should consider current 
literature supporting the use of stimulant medications for ADHD, and avoid harboring concerns 
from the past.  Further research may choose to focus on dose-related effects of stimulant 
medications to determine variability in cardiovascular response. Overall, research should 
continue to monitor long-term cardiac outcomes as the population of patients with adult ADHD 
continues to grow. The literature regarding substance abuse is clear in demonstrating increased 
risk throughout the lifetime, however it is limited because of the lack of control trials. Obviously 
substance abuse is not a phenomenon that can be tested in a lab. However, future studies should 
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determine which ADHD medications may have the greatest protective effects, and how age of 
onset of therapy affects future substance abuse. Both patients and providers would benefit from 
stronger evidence in this area. The evidence regarding adult ADHD is very limited by the current 
nature of data. Since it is a relatively new topic of interest, the majority of data is demographical 
and qualitative. However, the evidence presented here provides enough reason for providers to 
consider the importance of stimulant medication therapy in adulthood.  
 The global limitations of this summary are the specific focus on stimulant medications 
and their impact on ADHD. ADHD is a dynamic disorder and requires careful consideration on 
multiple levels by providers and patients alike. Treatment for ADHD has largely been aimed at 
symptom control, and the progression of symptoms throughout the lifetime is still a topic of 
some debate. There are studies to suggest that non-stimulant therapy may be more beneficial as 
patients transition from adolescence to adulthood. Because this literature review focuses 
exclusively on stimulant medication, the recommendations herein may be inappropriately one-
sided.   
In conclusion the results of this literature review demonstrate the cardiovascular safety of 
long-term use of stimulant medications. These findings coincide with over a decade of similar 
research demonstrating both efficacy and safety in children. Future research should focus 
exclusively on adult populations and how initiation of stimulant-therapy may impact existing 
comorbid conditions such as hypertension. The investigation of substance abuse should be 
continued to determine how stimulant medications for ADHD may reduce the lifelong impact of 
the disorder on substance abuse. Current and previous literature has established that the problem 
exists, now future research should seek to remedy it. The current literature regarding adult 
ADHD including quality of life and stimulant medications demonstrates without a doubt the 
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need for pharmacological treatment. There are no current guidelines for the treatment of ADHD 
diagnosed in adulthood, therefore many more studies are needed to determine the true incidence 
of adult ADHD as well as the most effective treatment regimens. Overall the long-term effects of 
stimulant medications for ADHD include benefits such as improved social, educational, and 
occupational outcomes. Serious adverse effects are rare and overall long-term use of stimulant 
medication is considered both safe and effective. Providers should feel equipped to use stimulant 
medications in patients of all ages to promote lifelong symptom management and control. 
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Article Matrix 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Agarwal, R., Goldenberg, M., Perry, R., 
& IsHak, W. W. (2012). The 
quality of life of adults with 
attention deficit hyperactivity 
disorder: a systematic review. 
Innovations in Clinical 
Neuroscience, 9(5-6), 10-21. 
The purpose of this 
study is to 
determine: 
 which metrics are 
used to assess 
quality of life (QOL) 
in adult ADHD 
What is the impact 
of adult ADHD on 
QOL? 
 What effects do 
ADHD treatments 
have on QOL 
Systematic review 
of literature using 
multiple databases 
including PubMed 
and Medline. 
Specific focus on 
studies that 
examined QOL of 
adult patients with 
ADHD, especially 
those using 
validated tools to 
quantify QOL. 
Reviewed a 
combination of 
qual/quant studies 
with a preference 
for quantitative 
data collected using 
valid QOL scales. 
 
Level V 
Sample size: 36 
24 studies used 
established QOL 
measures to quantify 
the QOL in adults 
with ADHD. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables: age, 
gender, stimulant 
medications, non-
stimulant medications, 
type of scale used for 
evaluation of QOL. 
 
Dependent variables: 
Reported QOL based 
on the above 
independent variables 
as measured by unique 
scales. 
 
QOL measures 
1)WHO-QOL brief 
version and SF-36. 
Self-rating of QOL 
based on four 
domains; physical, 
psychological, 
social, and 
environmental. 
Strong correlational 
value of level of 
Non-stimulant 
medications for 
ADHD 
(Amoxetine) do 
not decrease 
reported 
symptomology 
but do improve 
perceived QOL 
as rated by the 
patient. 
Stimulant 
medications 
(Adderall) 
decrease 
symptomology 
and improved 
executive 
functioning and 
improved QOL 
based on 
established 
metrics. 
Patients with 
ADHD report 
lower QOL and 
It is understood that 
adults with ADHD 
experience 
decreased QOL 
secondary to their 
ADHD symptoms. 
Because QOL 
measures have been 
proven to be valid 
and reliable, they are 
an important tool for 
goal setting and 
outcome measuring 
during 
pharmacologic 
therapy.  
Further research in 
the form of head to 
head trials would be 
beneficial to 
determine QOL 
improvement among 
individual classes of 
ADHD medications 
to determine 
superiority.  
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symptomology and 
QOL.  
2)QLESQ-S 
Rating scale 
demonstrating poor 
QOL in adults with 
ADHD and 
improved QOL in 
those taking 
stimulant 
medications 
3)AAQOL 
Specific for adult 
ADHD; 29 items, 
health-related QOL. 
4)AIM-A 
Assesses both global 
and ADHD specific 
QOL using six 
domains. Sensitive 
enough to 
discriminate 
symptom severity 
and medication 
subtype (a=>0.83) 
All metrics were 
demonstrated to be 
valid and reliable by 
the researchers. 
demonstrate 
increased 
incidence of 
anxiety, 
depression, and 
daytime 
sleepiness. 
Specifically, poor 
social functioning 
in men and poor 
emotional control 
in women. 
 Current metrics 
do not yet 
identify what 
leads to 
decreased QOL 
and decreased 
sense of 
wellbeing in 
ADHD.  
 QOL improved 
greatest in those 
receiving 
stimulant therapy, 
followed by non-
stimulant therapy, 
and placebo.  
 
 
 
 
 
 
 
 
 
 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Awudu, G. H., & Besag, F. C. (2014). 
Cardiovascular effects of 
methylphenidate, amphetamines 
and atomoxetine in the 
treatment of attention-deficit 
hyperactivity disorder: an 
update. Drug Safety, 37(9), 661-
676. doi:10.1007/s40264-014-
0201-8 
 
To provide an update 
on the available 
evidence for any 
effects of 
methylphenidate, 
dexamphetamine, and 
atomoxetine on heart 
rate, blood pressure, or 
sudden cardiac death. 
The reviewers 
published known 
information regarding 
the same topic in 
2009, this publication 
is considered an 
update.  
5 key concepts 
1) Methylphenid
ate and heart 
rate and 
blood 
pressure 
2) Atomoxetine 
and heart rate 
Review of 
literature published 
since 2009 
composed of 
articles from the 
PubMed/Medline, 
Embase, 
PsycINFO, the 
Wolters and 
Kluwer OVID 
database, and the 
SAGE journal 
database. Using 
terms ADHD, 
cardiovascular/card
iac, heart rate, 
blood pressure, or 
QTc. Specific drug 
names were also 
included in the 
Boolean search.  
20 papers were 
originally chosen 
for meta-analysis 
however due to 
A total of 41 articles 
were reviewed and 
referenced. 
9 studies discussed 
effects of 
methylphenidate on 
HR and BP in 
children and 
adolescents 
8 studies discussed 
effects of 
Atomoxetine on HR 
and BP in children 
and adolescents 
7 studies discussed 
the effects of 
amphetamines on 
HR and BP in 
children and 
adolescents 
5 studies discussed 
ECG changes with 
ADHD medications 
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and blood 
pressure. 
3) Amphetamin
es and heart 
rate and 
blood 
pressure 
4) Electrocardio
gram changes 
with ADHD 
medication 
5) Sudden death 
and ADHD 
medication 
lack of 
standardized 
measurements on 
among studies it 
was determined the 
literature would be 
synthesized using 
tables when 
appropriate.  
 
Level V 
6 studies discussed 
sudden death and 
ADHD medication 
Not all of these 
studies discussed 
HR and BP as 
primary outcomes.  
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables: age, 
gender, equipment 
used for monitoring 
HR and BP, 
equipment used for 
ECG monitoring, dose 
of ADHD medication, 
 
Controls: length of 
therapy at 
measurement 
intervals, normal BP 
readings for age based 
on established 
guidelines 
 
Dependent: HR, BP, 
and ECG changes as a 
result of duration of 
therapy. ( not dose 
dependent)  
Methylphenidate 
5/9 studies 
demonstrated 
statistically 
significant increase 
in HR at 90 min 
from 
administration of 
methylphenidate 
with a mean of <6 
bpm. From a long 
term perspective 
data points up to 6 
months did not 
demonstrate a 
clinically 
significant change 
in HR or BP. One 
study did report a 
clinically 
significant increase 
in HR at 14 months 
followed by a 
clinically 
significant decrease 
at 3 and 8 years 
respectively. 
Atomoxetine 
No studies to 
determine 
immediate effects 
(within two hours 
of administration). 
No statistically 
significant changes 
in BP or HR up to 
6 months. At 12 
months a 
statistically 
significant increase 
This update of the 
current literature 
demonstrates a 
significant gap in 
recent studies that 
investigate the 
cardiovascular 
safety of ADHD 
medications over the 
long-term. Less than 
5 of the reviewed 
studies collected 
data >5 years. Long-
term studies with 
specific interest in 
cardiovascular 
outcomes are needed 
to determine the 
overall safety of 
these medications. 
Beyond this data, 
this update does not 
demonstrate any 
new findings in 
regards to clinically 
significant ECG 
changes, changes in 
HR, BP, or risk of 
sudden death.  
 
Weaknesses of 
current studies are 
lack of allowance 
for age related 
changes in HR and 
BP which are 
considered normal. 
These measures 
should account for 
age progressions and 
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in HR (+3.26+-
14.32) was noted. 
Overall transient or 
marginal increases 
in BP and HR 
occurred but were 
not considered 
clinically relevant.  
Amphetamines 
Results limited by 
small number of 
studies since 2009, 
None of the studies 
examined cardiac 
outcomes as a 
primary endpoint. 
However, all 
studies reported a 
small <6 bpm 
increase in HR. No 
statistically 
significant changes 
in SBP or DBP 
were identified. 
However, attention 
was paid to outliers 
and further study 
revealed family 
history of CAD and 
MI in patients who 
present with 
elevated SBP.  
ECG Changes 
No clinical data 
supported ECG 
changes included 
prolonged QTI or 
arrhythmias in 
patients taking 
methylphenidate, 
amphetamines, or 
atomoxetine. May 
be limited by small 
sample size and 
lack of ECG 
changes as primary 
study outcome.  
Sudden Death 
As it relates to 
suicide, there is a 
known increased 
risk of suicide 
completion among 
patients with 
ADHD, no 
correlation has 
measure changes 
from baseline with 
respect to these 
values. 
 
Dose dependent 
studies would also 
be useful to 
determine how 
immediate release 
versus extended 
release medications 
may affect HR and 
BP in the short and 
long terms.   
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been identified 
between 
medication for 
ADHD and 
incidence of 
suicide; may be 
attributed to 
characteristic 
impulsivity. No 
studies 
demonstrated 
increased risk of 
sudden cardiac 
death in patients 
taking medication 
for ADHD as 
compared to the 
general population. 
Because of the 
relative low risk of 
sudden death in 
children and 
relatively increased 
risk of sudden 
death in adults, age 
parameters are an 
important 
distinction.  
 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Barbaresi, W. J., Colligan, R. C., 
Weaver, A. L., Voigt, R. G., 
Killian, J. M., & Katusic, S. K. 
(2013). Mortality, ADHD, and 
psychosocial adversity in adults 
with childhood ADHD: a 
prospective study. Pediatrics, 
131(4), 637-644. 
 
The goal if this study 
is to provide 
information regarding 
the cumulative risk for 
adverse long-term 
outcomes associated 
with childhood 
ADHD. This study 
describes mortality 
risks into adulthood 
which have not been 
previously identified.  
Outcomes of interest: 
1)Mortality 
secondary to suicide 
or accidents 
2)Incarceration rate 
3)Persistence of 
ADHD into 
adulthood and risk of 
comorbid psychiatric 
conditions 
Prospective cohort 
study comprised of 
a population based 
sample determined 
from existing 
school and health 
facility records. 
This information 
was used to 
determine vital 
status and its 
correlation with 
diagnosis of 
ADHD and was 
compared to 
standardized 
mortality ratios for 
the same 
population (control 
group). For 
determination of 
incarceration, adult 
ADHD status and 
other psychiatric 
disorders mailings 
Study participants 
were selected from a 
birth cohort 
(1/1/1976- 
12/21/1982) based 
on residence in 
Rochester, MI until 
>5 years of age and 
having previously 
granted permission 
to access medical 
records N=5718. 
Subjects were then 
determined to have 
ADHD based on 
these records 
N=367. The control 
group was 
established from the 
remaining subjects 
not including those 
with severe 
disability or who 
had denied further 
access to their 
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and follow up 
phone calls were 
used combined 
with public 
websites with 
information 
regarding criminal 
convictions. A 
standardized 
neuropsychiatric 
interview was 
administered.  
 
Level IV 
records. Of the 367 
eligible ADHD 
subjects, 232 agreed 
to participate in the 
prospective study. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables: gender, 
age, type of ADHD 
treatment during 
childhood, 
sociodemographic 
factors during 
childhood  
 
Dependent variables: 
mortality, 
incarceration rate, risk 
of comorbid 
conditions  
 
Measurements 
For determination of 
vitality, data was 
simply collected and 
the risk for specific 
outcomes mortality 
was determined by 
comparing the 
percentage prevalence 
of each outcome in the 
ADHD population 
versus the control.  
Mini international 
Neuropsychiatric 
interview (M.I.N.I.) 
with the adult module 
for ADHD was 
administered to all 
prospective study 
participants. 
Determination of adult 
ADHD was defined by 
the persistence of 
symptoms of 
inattention, 
Mortality 
Cause related 
mortality for 
accidents was 
similar among 
controls and 
ADHD cases.  
Cause related 
mortality for 
suicide was 
significantly higher 
among ADHD 
cases than controls. 
Further 
investigation 
determined that of 
the 7 ADHD case 
related deaths, 5 
had a documented 
history of 
substance abuse 
disorder and 1 
other psychiatric 
comorbidity. 
Incarceration 
2.7% of identified 
ADHD subjects 
were incarcerated 
at the time of this 
report, due to data 
collection 
limitations, rates of 
incarceration over 
the lifespan were 
not included. 
Persistence of 
ADHD into 
adulthood and 
comorbid 
Significant 
associations between 
childhood ADHD 
and adult psychiatric 
conditions 
demonstrate a need 
for continued 
research to 
determine the 
effectiveness of 
ADHD therapy into 
adulthood and how 
it may moderate 
these risk factors.  
Further research is 
needed to determine 
the rate of 
incarceration as it 
relates to childhood 
ADHD. Overall 
mortality from 
suicide is still not 
completely 
understood and 
requires further 
research. Substance 
abuse is an of great 
clinical concern and 
should be assessed 
frequently in 
adolescent and adult 
ADHD patients.  
EFFECTS OF STIMULANT MEDICATIONS FOR ADHD 27 
 
hyperactivity, and 
impulsivity with >4 
symptoms being 
present.  
psychiatric 
disorders 
Adults with ADHD 
were significantly 
more likely to have 
a comorbid 
psychiatric disorder 
than the control 
group (56.9 % 
versus 34.9%), The 
most common adult 
problems being 
alcohol abuse, 
antisocial 
personality 
disorder, other 
substance abuse, 
and generalized 
anxiety disorder. 
Total cases 
reporting both adult 
ADHD and 
comorbid 
psychiatric disorder 
N= 55, cases 
reporting adult 
ADHD only N= 13 
 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Brod, M., Schmitt, E., Goodwin, M., 
Hodgkins, P., & Niebler, G. 
(2012). ADHD burden of illness 
in older adults: a life course 
perspective. Quality of Life 
Research, 21(5), 795-799 5p. 
doi:10.1007/s11136-011-9981-9 
 
Purpose 
To explore the burden 
of illness and impact 
on the patients’ quality 
of life experiences in 
older ADHD adults. 
  
A qualitative pilot 
study to determine 
impact of ADHD 
symptoms on daily 
functioning, social, 
psychological, and 
physical well-being 
throughout the life 
course. 
 
Method 
Telephone 
interviews were 
conducted over 60-
90 minutes using 
an interview guide 
to collect the 
following data; 
demographic 
background, 
employment status 
and history, 
diagnoses, ADHD 
medications and 
symptom history, 
experience with 
Letters seeking 
referrals were sent to 
188 psychologists. 
Inclusion criteria 
were ADHD 
diagnosis by health 
care professional, 
English speaking, 
and age >60.  
 
27 patients were 
referred, 24 met 
criteria for 
completion.  
 
Mean age of sample 
was 66, mean age of 
ADHD diagnosis 
was 57.  
68% of the sample 
were mean. 99% 
Caucasian.  
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and perception of 
living with ADHD.  
The adult ADHD 
quality of life 
measure if a 
validated tool 
which was also 
completed by each 
respondent.  
 
Level VI 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
Age, gender, race, 
adult onset ADHD, 
ADHD diagnosis by 
healthcare provider, 
English language. 
Dependent 
treatment history, 
primary symptoms and 
impairments, positive 
aspects of ADHD, and 
burden of ADHD 
across the life course 
 
Qualitative researchers 
conducted, recorded, 
and transcribed the 
interviews. Results 
were coded for 
analysis. 
 
The AAQoL was used 
to quantify QOL 
perceived by 
participants. Results 
were compared to the 
control for the AAQoL 
validation study.  
Treatment 
History 
50% of participants 
report seeking 
treatment after self-
identifying ADHD 
symptoms. 100% 
of participants took 
medication for 
ADHD at some 
point and 22/24 
reported benefits 
including improved 
focus, listening, 
and reading 
comprehension. 
25% reported 
medication side 
effects; nausea, 
insomnia, 
headache, and 
anxiety 
Primary 
Symptoms and 
Impairments 
Inattention was 
reported by 71%, 
impulsivity 58%, 
hyperactivity 54%, 
and disorganization 
54%.  
Positive aspects of 
ADHD 
46% of participants 
believed ADHD 
made them more 
creative and able to 
hyper focus when 
interested in a 
topic. 
Burden of ADHD  
63% of participants 
reported a tangible 
This study supports 
the hypotheses that 
adult ADHD 
symptoms have a 
meaningful long-
term effect on QOL 
in the form of career 
success, social 
relationships, and 
financial 
management.  
This small sample 
size and qualitative 
data cannot be 
generalized to larger 
populations, 
however as the rates 
of adult ADHD 
diagnosis increase, 
so will the 
population of older 
adults with ADHD. 
 
Future studies and 
current treatment 
measures should be 
aimed at minimizing 
these negative 
impacts across the 
lifespan.  
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cumulative impact 
of their ADHD on 
their finances 
related to 
impulsivity and 
inability to manage 
debt.  
71% stated their 
ADHD had 
alienated friends, 
family, and co-
workers. 
Assessment of 
ADHD on QOL 
The mean age of 
the comparison 
group was 41, but 
the questionnaire 
demonstrated a 
significantly lower 
life productivity 
score in the older 
adult. However, the 
life outlook score 
was significantly 
better compared to 
the younger 
sample.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Chang, Z., Lichtenstein, P., Halldner, L., 
D'Onofrio, B., Serlachius, E., 
Fazel, S., & ... Larsson, H. 
(2014). Stimulant ADHD 
medication and risk for 
substance abuse. Journal of 
Child Psychology And 
Psychiatry, And Allied 
Disciplines, 55(8), 878-885. 
doi:10.1111/jcpp.12164 
 
The purpose of this 
study is to determine 
the effects of long-
term use of ADHD 
medications as they 
relate to substance 
abuse. There is a 
known correlation 
between the diagnosis 
of ADHD and 
substance abuse, but 
inconclusive data 
about how medication 
for ADHD may 
contribute to substance 
abuse as well.  
Population based 
longitudinal cohort 
study.  
Data were analyzed 
using cox 
regressions with 
standard errors. 
Specific controls 
were used to isolate 
the outcome of 
interest as it 
pertains to the 
general population 
and to avoid 
inappropriate 
skewing. The 
outcome of 
substance abuse for 
example was 
examined in 
patients based on 
covariates of civil 
employment, 
education, urban 
living, and family 
income. Previous 
A Swedish 
population based 
sample of nation-
based register of 
persons born from 
1960-1998 with a 
diagnosis of ADHD 
based on the ICD 10 
code F90 and known 
treatment via the 
prescription drug 
register. Substance 
abuse was identified 
using national 
patient cause of 
death and crime 
registries. 
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substance abuse, 
criminal 
convictions (other 
than substance 
abuse) and other 
psychotropic 
medications were 
also taken into 
account. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables: Age, 
gender, age of ADHD 
diagnosis, type of 
ADHD medication, 
duration of treatment, 
and individual controls 
as previously 
described.  
Dependent 
Variables: incidence 
of substance abuse 
with respect to 
covariates.  
 
Hazard ratio for 
substance abuse 
Calculated using Cox 
regressions comparing 
medicated and non-
medicated periods to 
quantify the risk of 
substance abuse with 
controls for various 
social/demographic 
variables.  
Patients who were 
not taking ADHD 
medications in 
2006 were 
compared to those 
taking medications 
in 2006 and data 
was recovered from 
2009 to determine 
long-term effects 
and trends in 
substance abuse. 
Analysis were also 
done on the basis 
of sex and age. 
These analyses 
determined there 
was a 48* decrease 
in the substance 
abuse ratio HR= 
0.52 95% 
confidence interval 
among patients 
who were 
medicated for their 
ADHD versus 
those who were 
not. Furthermore, 
after controlling for 
criminal 
convictions prior to 
2006, previous 
substance abuse, 
and 
sociodemographic 
factors such as low 
income there was 
still a 31% 
decrease in 
substance abuse 
among medicated 
patients with 
ADHD.  
 
This information 
should encourage 
community based 
providers to feel 
more comfortable 
when prescribing 
medications for 
ADHD. Despite 
popular opinion and 
black box warnings, 
this study did not 
demonstrate 
correlation or 
causation among 
ADHD medications 
and propensity for 
substance abuse. If 
anything ADHD 
medications can be 
protective against 
substance abuse in 
ADHD patients.  
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Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Groenman, A. P., Oosterlaan, J., 
Rommelse, N., Franke, B., 
Roeyers, H., Oades, R. D., & ... 
Faraone, S. V. (2013). 
Substance use disorders in 
adolescents with attention 
deficit hyperactivity disorder: a 
4-year follow-up study. 
Addiction, 108(8), 1503-1511 
9p. doi:10.1111/add.12188 
 
Purpose 
To examine the 
relationship between a 
childhood diagnosis of 
attention deficit 
hyperactivity disorder 
(ADHD) 
with or without 
oppositional defiant 
disorder 
(ODD)/conduct 
disorder (CD) and the 
development of later 
alcohol/drug 
use disorder 
[psychoactive 
substance use disorder 
(PSUD)] and nicotine 
dependence. 
 
Prospective 
population based 
cohort 4-year 
follow up study. 
 
Subjects from 
IMAGE study age 
5-17 years with one 
available sibling 
(not required to 
have ADHD 
diagnosis) 
 
Data collection was 
done via in person 
interviews at 1 of 
the three sites. 
Parent and teacher 
Connor’s rating 
scales were part of 
baseline data to 
quantify ADHD 
symptoms 
 
Data were analyzed 
based on 
prevalence rates 
and hazard ratios 
compared to 
control. 
 
Level IV 
Participants from the 
Belgian, Dutch, and 
German part of the 
International 
multicenter ADHD 
genetics (IMAGE) 
study. 
Age 5-17 years 
attending outpatient 
clinics, and one of 
their siblings, and 
control groups from 
the same geographic 
area. 
Mean age of re-
assessment 16.4 
years 
N= 1017 
ADHD N=511 
Unaffected sibling 
N=286 
Healthy control 
N=220 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, race, gender, 
diagnosis of ADHD, 
diagnosis of 
oppositional defiance 
disorder, diagnosis of 
conduct disorder 
Dependent variables 
substance use 
diagnosis, alcohol use, 
alcohol dependence, 
nicotine use, nicotine 
dependence, age of 
use 
 
Parental account of 
childhood symptoms 
(PACS) interview was 
conducted at baseline 
The population of 
children with 
ADHD were 1.8 
times more likely 
to develop 
psychoactive 
substance use 
disorder and 8.6 
more likely to 
develop nicotine 
dependence than 
healthy controls. 
 
Unaffected siblings 
were not at 
increased risk for 
PSUD or nicotine 
dependence.  
 
This large 
population based 
study demonstrated 
an increased risk of 
substance abuse and 
nicotine use in 
adolescents for 
children who are 
diagnosed with 
ADHD. These 
findings correlate 
with other published 
studies that 
demonstrate a 
positive correlation 
between ADHD and 
substance abuse. 
 
This study does not 
address treatments 
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PACS and Connor’s 
scales were used to 
supply operational 
definitions to 
characteristics 
associated with 
ADHD 
 
Alcohol user’s 
identification test 
(AUDIT) Scores form 
0-40  
9 or greater indicated 
alcohol abuse 
And greater than 15 
was alcohol 
dependence 
 
Drug abuse screening 
test (DAST) scores 0-
20. Cutoff of 5 for 
possible drug use 
disorders 
 
Fagerstrom test for 
nicotine dependence 
(FTND) scored 0-10. 
Cutoff of 6 indicated 
nicotine dependence. 
 
Criteria may be met by 
individual or parent 
report data alone 
 
ADHD and 
comorbid conduct 
disorder increased 
incidence of 
PSUD.  
ADHD and ODD 
did not increase 
risk compared to 
healthy control 
group. 
 
Participants with 
childhood ADHD 
diagnosis had 
younger age of first 
substance use and 
nicotine use 
compared to 
healthy controls.  
Unaffected siblings 
had a younger 
onset of nicotine 
use compared to 
healthy controls. 
for ADHD to 
determine if patients 
were or were not on 
therapy at the time 
of diagnosis or the 
time of follow-up. 
Knowing whether or 
not patients who 
exhibited substance 
abuse disorders were 
treated for their 
ADHD is very 
important for future 
practice.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Habel, L., Cooper, W., Sox, C., Chan, K., 
Fireman, B., Arbogast, P., & ... 
Ray, W. (2011). ADHD 
medications and risk of serious 
cardiovascular events in young 
and middle-aged adults. JAMA: 
Journal Of The American 
Medical Association, 306(24), 
2673-2683 11p.  
Purpose 
To examine whether 
current use of 
medications prescribed 
primarily to treat 
ADHD is associated 
with increased risk of 
serious cardiovascular 
events in young and 
middle-aged adults. 
Large 
retrospective, 
population-based 
cohort study 
utilizing chart 
review from four 
different facilities. 
Beginning in 1986 
and ending in 2005.  
 
Level IV 
adults aged 25 
through 64 years 
with dispensed 
prescriptions for 
methylphenidate, 
amphetamine, or 
atomoxetine at 
baseline and 2:1 
controls chosen to 
match cases for site, 
birth year and sex.  
N=443,198 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
age, sex, data site, 
calendar year at cohort 
entry, duration of 
In all groups 
including current 
users, remote users, 
and non-users there 
were no indications 
Because data was 
collected using 
prescription 
database and 
insurance database 
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therapy, type of 
ADHD medication 
Dependent variables 
MI 
Sudden cardiac death 
Stroke 
Other serious 
cardiovascular event 
 
Cardiovascular risk 
score (CRS) was 
created to allow for 
cofounders that would 
affect the endpoints 
but are not related to 
medication for ADHD 
I.e. use of 
psychotropic 
medications, diabetes 
mellitus, obesity, 
smoking-related and 
health care utilization   
 
Multi-variate logistic 
regression was used to 
account for other non-
controlled confounders 
such as family history 
of CVD, substance 
abuse, and ethnicity.  
that risk rations 
were increased for 
any of the 
endpoints of 
interest. Once the 
results were 
mitigated using the 
CRS and analysis 
of race, etc. There 
were still no 
statistically 
significant 
indicators that 
ADHD mediation 
use part or present 
resulted in 
increased incidence 
of serious 
cardiovascular 
events.  
 
 
information it does 
not necessarily 
reflect results of 
medication 
compliance, since 
medications may 
have been prescribed 
and not taken. 
Because of the large 
sample size, it is 
reasonable to 
assume that these 
findings can be 
generalized to 
general practice.  
Higher levels of 
evidence using 
controlled trials are 
difficult because of 
the length required 
for the observation 
of study outcomes.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Hammerness, P. G., Surman, C. H., & 
Chilton, A. (2011). Adult 
attention-deficit/hyperactivity 
disorder treatment and 
cardiovascular implications. 
Current Psychiatry Reports, 
13(5), 357-363. 
doi:10.1007/s11920-011-0213 
To provide an update 
on currently approved 
medications for 
ADHD with focus on 
cardiovascular risk 
factors associated with 
sympathomimetic 
mechanisms of action. 
 
Review of 
literature from 
2009 to 2011 based 
on PubMed 
database search. 
Search limiters: 
adult, clinical trials, 
English language. 
Also including 
guidelines 
published by the 
AAP and AHA.  
 
Level II 
A total of 50 articles 
were listed in the 
review of literature, 
the majority of the 
implications in the 
article were 
demonstrated from 4 
large sample size 
studies N= 
226,420,359, and 
133 respectively. 
With a preference 
for long term data 
points including one 
study with data 
collected over 24 
months.  
 Variables, 
Measurements 
Findings Future Implications 
 Variables of interest in 
each study were HR, 
resting and active, 
systolic and diastolic 
Stimulant class 
medications  
Trends in RCT 
demonstrated an 
increase in HR (4-
Stimulant 
medications are still 
considered most 
effective therapy in 
adults and are 
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blood pressure, and 
ECG changes.  
Independent variables 
were age, gender, type 
of medication, 
medications dose, and 
age of diagnosis.  
 
Information was not 
given regarding how 
the measurements 
were recorded, rather 
the authors 
summarized the 
findings of each study 
and how they were 
significant to practice. 
10) BPM, increase 
in BP (1-5 mmHg) 
in healthy pre-
screened Adults. 
These markers vary 
throughout 
duration of therapy.  
As many as 60% of 
patients report 
subjective 
symptoms such as 
headache, dry 
mouth, drowsiness, 
and insomnia.  
Occurrence of 
subjective 
symptoms did not 
correlate with 
incidence of 
tachycardia or 
HTN. 
Non-stimulant 
Medications 
Based on measure 
of effect size, non-
stimulants are 
inferior to 
stimulants in 
regards to efficacy.  
RCT demonstrates 
mean elevations of 
5 BPM and 2 
mmHg for HR and 
BP. Amoxetine is 
also associated 
with increased 
subjective reports 
of palpitations, but 
fever reports of 
HA, and insomnia.  
 
No EKG changes 
were associated 
with stimulant or 
non-stimulant 
therapies. 
 
considered safe as 
supported by clinical 
date up to two years. 
Beyond that, further 
long-term studies are 
needed to determine 
cardiac adverse 
effects. 
Based on the 
literature for 
Amoxetine, it is 
considered second 
line therapy unless 
the patient 1) cannot 
tolerate stimulant 
secondary to 
insomnia or weight 
loss or 2) the patient 
has history of 
substance abuse. 
Also, secondary to 
its mechanism of 
action, Amoxetine 
shows greater 
emotional control 
and positive 
outcomes for 
women. 
This data is useful 
for prescribers.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Huang, Y., & Tsai, M. (2011). Long-term 
outcomes with medications for 
attention-deficit hyperactivity 
disorder: current status of 
knowledge. CNS Drugs, 25(7), 
539-554. 
Determine long term 
outcomes of 
medications for 
ADHD, overview of 
currently available 
data regarding 
stimulants and non-
Systematic review 
of literature. 
Specifically, open-
label longitudinal 
case-control or 
randomized 
controlled trials of 
Data retrieved using 
PubMed database 
with keywords long-
term outcomes of 
ADHD medications. 
All studies were 
published since 
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doi:10.2165/11589380-
000000000-00000 
 
stimulants. Highlight 
areas for further 
research.  
at least 6 months 
duration.  
 
 
Level III 
2001. A total of 128 
articles were 
reviewed. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, sex, dose of 
medication, stimulant 
versus non stimulant 
medication, age of 
diagnosis 
 
Dependent Variables 
Effectiveness, adverse 
effects (subjective), 
growth effects, 
cardiovascular effects, 
Tics and Tourette’s 
syndrome, substance 
abuse, quality of life, 
academic 
achievements in high 
school. 
 
Long term outcomes > 
5 years in children and 
long term outcomes in 
adulthood were 
describes separately 
regarding safety, 
efficacy, and 
tolerability.  
Effectiveness 
Medication therapy 
including stimulant 
and non-stimulant 
options was 
superior to 
behavioral 
cognitive therapy 
in effectiveness of 
symptom 
reduction. 
Both Amoxetine 
and stimulant 
therapy 
demonstrated long-
term clinical 
improvement from 
a period of 14-24 
months. At 36 
months of therapy, 
the advantages 
were less apparent. 
This may be 
attributed to age 
related changes in 
ADHD severity, or 
changes in intensity 
or adherence to 
therapy.  
Adverse Effects 
RCT evaluating 
stimulant 
medications over 
five years 
demonstrated 
persistence of 
headache, appetite 
loss, and 
abdominal pain to 
the final endpoint, 
however none of 
the participants 
discontinued the 
therapy due to 
these adverse 
effects, suggesting 
tolerability. 
Severity of 
reported side 
Stimulant and non-
stimulant 
medications are 
effective for treating 
ADHD throughout 
the lifespan 
regardless of age of 
diagnosis, more 
longitudinal studies 
are needed to 
determine specific 
safety and efficacy 
considerations. 
Stimulants are still 
considered first line 
in children and 
adults, however 
evidence suggests 
that in adulthood 
and in the presence 
of other comorbid 
psychiatric 
conditions 
Amoxetine may 
have greater impact 
on QOL of symptom 
reduction. 
Known adverse 
effects of stimulant 
medications appear 
to persist in long-
term therapy but are 
considered tolerable. 
Cardiovascular 
effects including 
increased HR and 
BP are small but 
further data is 
needed to determine 
the long-term risks. 
Medication for 
ADHD does not 
contribute to later 
substance abuse, and 
early initiation of 
therapy may have 
protective influences 
by limiting 
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effects varied 
among type of 
stimulant 
medications 
suggesting they 
could be managed 
by changing drug 
therapies.  
Growth Effects 
Similar to previous 
reports, the 
literature shows a 
delay in 
progression of 
height and weight 
at 12 and 15 
months of therapy 
which were 
recovered by 24-36 
months. This is true 
of stimulant and 
non-stimulant 
therapies.  
Cardiovascular 
Effects 
For Amoxetine and 
stimulant 
medications, small 
but statistically 
significant 
increases in BP 
were noted. 
Stimulant therapy 
also resulted in 
statistically 
significant 
increases in HR. 
Despite these 
changes, No EKG 
changes were 
noted, leading 
authors and 
researchers to 
determine the 
cardiovascular 
effects are 
manageable. 
Further research is 
needed to 
determine the long-
term implications 
of these changes.  
Therapy remains 
contraindicated for 
patients with 
history of cardiac 
impulsive and 
antisocial behaviors.   
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abnormalities, 
syncope, angina, or 
family history of 
sudden cardiac 
death.  
Tics and 
Tourette’s 
No evidence to 
suggest that 
stimulants increase 
the incidence of or 
exacerbate tics or 
Tourette’s. 
Substance Abuse 
Stimulants 
administered in 
childhood do not 
increase the risk of 
later substance 
abuse. 
One study 
demonstrated a 
positive 
relationship 
between age of 
treatment initiation 
and non-alcoholic 
substance abuse.  
Quality of Life 
Most data focuses 
on treatment with 
Amoxetine, as a 
generalization, 
studies demonstrate 
improved QOL in 
patients receiving 
treatment for 
ADHD compared 
to those who do 
not. 
Academic 
Achievements 
Patient’s receiving 
at least 1 year of 
stimulant therapy 
scored higher in all 
academic areas 
than those not 
being treated for 
their ADHD.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Kelly, A. S., Rudser, K. D., Dengel, D. 
R., Kaufman, C. L., Reiff, M. I., 
Norris, A. L., ... & Steinberger, 
J. (2014). Cardiac autonomic 
Purpose 
To compare markers 
of cardiovascular 
health in youth 
Cross-sectional 
observational study 
of children with 
ADHD taking 
N=138 children and 
adolescents 85 with 
ADHD and 53 
control participants 
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dysfunction and arterial stiffness 
among children and adolescents 
with attention deficit 
hyperactivity disorder treated 
with stimulants. The Journal of 
pediatrics, 165(4), 755-759 
diagnosed with ADHD 
by the use of stimulant 
medication with 
healthy controls. 
 
stimulant 
medications with a 
control group 
comparison. 
Data was collected 
by trained study 
staff and was 
standardized by 
direct observation 
of medication 
administration, and 
standards of 
measure for heaight 
weight, HR, and 
BP.  
SphyhmoCor MM3 
systems measured 
HR variability and 
magnitude of pulse 
wave velocity to 
determine arterial 
stiffening. 
 
Level IV 
from an outpatient 
pediatric clinic. 
ADHD patients must 
be taking stimulant 
medication either 
Adderall or 
methylphenidate 
derivative. 
Exclusion criteria 
were known 
cardiovascular 
disease.  
Mean cumulative 
stimulant treatment 
for the group was 
approx. 3 years. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
Age, gender, height, 
weight, BMI, length of 
therapy, Tanner stage 
of development, 
caffeine consumption 
by participants, time 
engaging in vigorous 
exercise for the past 
14 days (28% in 
control and ADHD 
groups) 
 
Dependent 
Blood pressure, heart 
rate, heart rate 
variability, carotid-
radial pulse wave 
velocity, carotid artery 
augmentation index, 
radial artery 
augmentation index, 
brachial artery flow-
mediated dilation, and 
digital reactive 
hyperemic index.  
Indices were measures 
using the sphygmoCor 
MM3 system and 
standard ultrasound 
Mean age and 
Tanner stage 
distribution were 
similar among 
groups. ADHD 
group 
demonstrated lower 
mean BMI than 
control group.  
ADHD group had 
greater resting SBP 
(3.9 mm Hg), 
greater resting HR 
(+9.2 BPM), 
carotid artery 
augmentation index 
(AIx) (7.2%), and 
pulse wave velocity 
(0.36 m/s). No 
statistically 
significant 
differences in the 
groups for radial 
augmentation 
index.  
These results 
demonstrate 
increased HR 
variability and 
arterial stiffening in 
Because the control 
group in this study 
was comprised of 
healthy children 
without ADHD it is 
impossible to say if 
the increased 
variability in HR 
and arterial stiffness 
is related to the 
stimulant medication 
or is attributed to the 
underlying 
pathology of ADHD 
itself.  
 
A further 
longitudinal study 
with participants 
who have ADHD 
but are not receiving 
stimulant 
medications would 
be needed to 
determine causation.  
 
Because this study 
evaluates these 
effects in the acute 
setting, further 
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Measures were taken 
at intervals up to 90 
minutes after 
medication ingestion.  
 
Statistical analysis was 
performed using t-test 
for covariates and 
robust variance 
estimation was used 
for Cis and P values. 
the population of 
patients with 
ADHD. 
 
Based on the data 
analysis, elevation 
in HR and BP were 
casual but not 
directly correlated 
to HR variability 
and arterial 
stiffness.  
 
These findings 
indicate greater 
sympathetic 
activation resulting 
in more extreme 
values in children 
with ADHD than 
have previously 
been observed in 
children with type I 
DM or childhood 
obesity, which are 
known 
cardiovascular risk 
factors.  
 
There was no 
statistically 
significant 
difference among 
results in patients 
based on duration 
of therapy or dose 
of stimulant 
medication.  
research is needed to 
determine how they 
persist over time.  
 
Because HR 
variability and 
arterial stiffness are 
known independent 
risk factors of 
cardiovascular 
disease it is 
important to 
determine if these 
effects are in fact 
caused by the use of 
stimulant 
medications and if 
persist through long-
term therapy.  
 
These measures are 
more indicative of 
cardiovascular risk 
than HR and SBP 
measurements alone 
and should be used 
as standard measures 
in future studies.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Klein, R. G., Mannuzza, S., Olazagasti, 
M. R., Roizen, E., Hutchison, J. 
A., Lashua, E. C., & 
Castellanos, F. X. (2012). 
Clinical and functional outcome 
of childhood attention-
deficit/hyperactivity disorder 33 
years later. Archives Of General 
Psychiatry, 69(12), 1295-1303. 
doi:10.1001/archgenpsychiatry.
2012.271 
 
Purpose 
To determine 
functional outcomes of 
childhood ADHD into 
the fourth and fifth 
decades of life (span 
33 years). 
 
Outcome Questions 
Occupational 
Economic 
Educational attainment 
Marital history 
Lifetime psychiatric 
disorders 
Incarcerations 
Prospective 33-
year follow-up 
study with masked 
clinical 
assessments. 
 
Follow up 
interviews 
conducted at 18 
years of age, 25 
years of age, and 
41 years of age. At 
41 years of age the 
final interviews 
were conducted by 
trained and 
The original sample 
was obtained by 
teachers referring 
white males age 6-
12 from years 1970-
1978. Boys were 
included if their 
referral criteria were 
impulsivity and 
hyperactivity 
without aggression, 
history of antisocial 
behavioral problems, 
and whose IQ was 
>85. The control 
group was selected 
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supervised doctoral 
level clinical 
psychology 
candidates masked 
to all antecedent 
data.  
 
Telephone and 
personal interviews 
were conducted.  
 
Level IV 
form white males of 
the same age who 
had existing medical 
records at the same 
medical record and 
were seen for minor 
acute conditions or 
routine medical care 
without 
documentation of 
behavioral problems.  
N= 135 men with 
childhood ADHD 
and 136 without. 
 
 Variables, 
Measurements 
Findings Future Implications 
  Independent 
variables 
Age, male gender, 
ADHD diagnosis 
based on behavioral 
documentation 
consistent with DSM-
IV criteria, absence of 
antisocial or 
neurologic disorder, 
education and training 
of interviewers.  
 
Dependent variables 
Reported social and 
functional outcomes. 
Education as 
determined by years of 
education and highest 
degree obtained.  
Occupational based on 
current employment 
status, job satisfaction, 
work relationships, 
lateness, job changes, 
and firings. These 
items were rated by 
interviewers on an 
anchored scale from 1-
6. (1) Superior (6) 
Poor 
Social function by 
inquiring about 
friendship, social and 
leisure activities, also 
rated on a 6-point 
scale. 
Incarceration (reform 
school or jail time of 
On average 
participants with 
ADHD had 2.5 
fewer years of 
school than 
controls as well as 
fewer high-level 
degrees.  
ADHD participants 
demonstrated lower 
occupational 
attainment levels 
(4.7 versus 3.0).  
Lower educational 
and occupation 
understandably 
resulted in lower 
socioeconomic 
status. The average 
salaries of the 
effected population 
versus the control 
differed by 
$40,000. 
Patients with 
ADHD 
demonstrated 3-
fold greater rate of 
non-alcohol 
substance abuse 
and nicotine 
dependence. There 
was no significant 
difference in 
occurrence of anti-
social personality 
disorders, anxiety, 
or mood disorders.  
Weaknesses 
requiring further 
study; study was 
limited to white 
male participants, 
excluding date for 
women or other 
races. No 
documentation of 
ADHD treatment in 
childhood or 
adulthood was 
provided so the 
augmentation of 
these lifelong risk-
factors by proper 
clinical 
identification and 
treatment cannot be 
postulated.  
This study is 
valuable because it 
evaluates the long-
term functional 
outcomes associated 
with the diagnosis of 
ADHD itself. 
However, further 
studies with diverse 
sample sizes and 
greater information 
about treatment 
methods and 
influences would be 
needed for this 
information to be 
considered 
generalizable and 
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more than one day) 
rated as positive or 
negative. 
Marital history as 
currently married or 
not, and history of 
divorce.  
Lifetime psychiatric 
disorders including 
anti-social personality 
disorder and substance 
abuse based on 
interviewer’s data 
collection and 
hospitalization in a 
psychiatric facility. 
 
Lifetime prevalence of 
ADHD symptoms was 
assessed based on 
participants reported 
experiences and 
interviewer’s 
assessment consistent 
with DSM-IV criteria.  
 
Patients with 
ADHD had higher 
rates on 
incarceration and 
divorce than the 
control  
 
Interviewer reports 
of adult ADHD 
symptomology 
based on DSM-IV 
criteria were 
significantly less 
than subjective 
perceived ongoing 
effects of adult 
ADHD.  
valuable to clinical 
practice. 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Lensing, M. B., Zeiner, P., Sandvik, L., 
& Opjordsmoen, S. (2015). 
Psychopharmacological 
treatment of ADHD in adults 
aged 50+: an empirical study. 
Journal Of Attention Disorders, 
19(5), 380-389 10p. 
doi:10.1177/1087054714527342 
 
Purpose 
To study 
pharmacotherapy in 
adults age 50 or older 
with ADHD 
 
Study Questions 
1) How well do 
stimulant 
medications 
work for this 
group of 
adults, many 
who have 
lived their 
whole lives 
undiagnosed 
and 
untreated? 
2) Can adults 
age 50+ 
tolerate 
pharmacother
apy?  
An Empirical study 
of use and 
persistence of 
psychopharmacolo
gical treatment for 
ADHD in older 
populations and to 
explore the 
association 
between treatment, 
symptoms, and life 
satisfaction. 
 
Anonymous survey 
of self-identified 
ADHD patients 
from a national 
ADHD patient 
organization.  
 
Likert scales 
allowed for 
quantitative data 
analysis using chi 
squared tests 
among categorical 
data, binary logistic 
regression analysis 
The survey was 
mailed to 251 
subjects who met 
inclusion criteria; 
diagnosis of ADHD 
by clinical specialist, 
and age >50. 166 
returned the survey. 
17 were excluded 
because either 
ADHD or age could 
not be confirmed 
 
N= 149 
 
59.7% female 
Mean age of 
participants 55.8 
Mean age of 
diagnosis  
50.3 
EFFECTS OF STIMULANT MEDICATIONS FOR ADHD 42 
 
was used to 
identify 
associations 
between 
characteristics and 
symptom severity.  
 
Level VI 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, Adult diagnosis 
of ADHD, gender, 
current or former 
treatment for ADHD, 
duration of treatment.  
Dependent variables  
Treatment impact on 
core symptoms of 
hyperactivity and 
inattention.  
Satisfaction of life, 
current health status, 
self-efficacy/ 
 
ADHD self-report 
scale (ASRS) four 
items of inattention 
and two items of 
hyperactivity/impulsiv
ity. Frequency rated 
on a 5 point Likert 
scale 0 (never)- 4(very 
often). Clinical cutoff 
was 14 
 
Health status assessed 
using Euroqol visual 
analogue scale (EQ-
VAS) values from 0-
100) 0 Being worst 
and 100 being best.  
 
Self-efficacy measured 
using the statement 
“IM able to manage 
daily demands well”.  
5 point Likert response 
from strongly disagree 
to strongly agree. 
Characteristics of 
the study sample 
were classified 
based on three 
groups; currently 
treated with 
medication, 
stopped treatment 
with medication, 
and never treated 
with medication for 
ADHD.  
 
87.9% had been 
treated using 
pharmacotherapy, 
95 of which were 
currently still being 
treated.  
 
Those who were 
currently being 
treated with 
medication 
reported better 
attention than the 
non-medicated 
groups. 
Participants who 
had never been 
treated for ADHD 
reported worse 
current health 
status than the 
other two groups.  
 
Self-efficacy was 
higher in groups 
still being treated 
for ADHD 
compared to those 
who had stopped 
treatment.  
 
The three groups 
did not differ 
Adults who were 
treated for their 
ADHD 
demonstrated 
increased attention 
and greater self-
efficacy than those 
that were not treated. 
 
There were no 
significant 
differences in 
hyperactivity/impuls
ivity or overall 
favorable outcomes 
(I.E. clinically 
insignificant 
experience of 
ADHD symptoms) 
among treated and 
non-treated groups. 
 
Further research is 
needed to determine 
how age related 
progression of 
ADHD and age 
related variations in 
neurotransmitter 
activity may 
influence efficacy of 
stimulant 
pharmacotherapy in 
older adults. 
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statistically 
significantly 
between favorable 
outcomes (ASRS 
<14). 
 
The majority of 
patients receiving 
pharmacotherapy 
for ADHD received 
methylphenidate. 
 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Mahon, A. D., Woodruff, M. E., Horn, 
M. P., Marjerrison, A. D., & 
Cole, A. S. (2012). Effect of 
stimulant medication use by 
children with ADHD on heart 
rate and perceived exertion. 
Adapted Physical Activity 
Quarterly: APAQ, 29(2), 151-
160.  
 
Purpose 
To examine the rating 
of perceived physical 
exertion-heart rate 
relationship during a 
graded exercise test 
performed to peak 
exertion in children 
with ADHD presently 
using stimulant 
medications compared 
with similarly aged 
children without 
ADHD.  
Cross-sectional 
case control study. 
HR and RPE to be 
measured in study 
and control 
population during a 
standardized 
graded exercise 
test. 
Standardized RPE 
scale was used. 
Children were 
taught how to use 
the scale and then 
had a post-test 
evaluation for 
understanding. 
Exercise was done 
on an 
electronically-
braked cycle 
ergometer; HR was 
measured using 
Polar monitors. 
Measures of peak 
HR and power 
output were 
recorded with the 
RPE. 
Data were plotted 
and analyzed by 
slope and intercept. 
Means and SD 
were determined 
for each group. 
 
Level IV 
Participants 
volunteered for 
study and 
participants and 
parents consented to 
procedures. N=45, 
20 children with 
ADHD and 
receiving stimulant 
medications (18 
boys, 2 girls), 25 
children without 
ADHD (12 boys, 13 
girls).  
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
There were no 
significant 
differences in 
Because current 
studies are being 
done to determine 
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Age, stature, mass, 
type of medication, 
daily medication dose, 
equipment used for 
measuring HR and 
power output. 
RPE rating scale- 
values from 1-10 
based on level of 
exertion 
 
Dependent variable 
Heart rate; resting and 
during maximum 
output, power output, 
and RPE 
measurement.  
 
Peak HR was taken as 
the highest two 
consecutive averages 
recorded during the 
test. Peak power 
output measured in W 
was prorated by 
duration of highest 
achieved test stage. 
Physical 
characteristics and 
peak exercise response 
were compared 
between groups using 
independent t-test. 
physical 
characteristics 
among either 
group.  
Peak HR for both 
groups= 200 
Power output 
(W/Kg) = 3.1 in the 
ADHD group and 
2.8 in the control 
group. Mean RPE 
for both groups 9.8. 
 
The relationship of 
HR to RPE was 
determined by 
plotting slope and 
intercept. For the 
participants with 
ADHD mean 
intercept (bpm) 
were 132.4 
whereas the mean 
intercept for the 
control group was 
120.6. The slope 
(bpm/RPE) for the 
ADHD group was 
7.3, and 8.1 in the 
control group.  
 
For children with 
ADHD taking 
stimulant 
medications at a 
given HR RPE will 
be lower and at a 
given RPE HR will 
be higher when 
compared to 
control. This could 
be due to an 
elevated resting 
HR. The greatest 
effect was 
demonstrated at 
lower intensities, 
and the effect 
began to level off 
as maximum HR 
was achieved. 
the benefits of 
exercise therapy for 
children with ADHD 
it is important to 
note the differences 
in perceived exertion 
and heart rate.  
 
It is unknown if 
children adapt to the 
higher resting heart 
rate over time or 
how titrating 
medication dosages 
effect perceived 
exertion and HR. 
 
It is however 
important for 
clinicians to note 
that exertional 
efforts of children 
being treated with 
stimulant 
medications may not 
be accurately 
reflected by their 
subjective 
experiences of 
exertion.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Martinez-Raga, J., Knecht, C., Szerman, 
N., & Martinez, M. I. (2013). 
Risk of serious cardiovascular 
Purpose 
To comprehensively 
and critically review 
Comprehensive 
search of relative 
databases 
81 documents were 
included for the 
review based on 
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problems with medications for 
attention-deficit hyperactivity 
disorder. CNS Drugs, 27(1), 15-
30. doi:10.1007/s40263-012-
0019-9 
published evidence on 
association of 
medications for 
ADHD and risk of 
serious cardiovascular 
problems including 
QT/QTc prolongation 
and risk of sudden 
death in children, 
adolescents, and adults 
(PubMed, 
EMBASE, and 
PsychINFO) for 
peer-reviewed 
publications up 
until July 21, 2012.  
Key terms: ADHD, 
amphetamine, 
Amoxetine, 
clonidine, 
guanfacine, 
methylphenidate, 
arrhythmia, 
cardiac, QT, 
sudden death and 
torsade’s de 
pointes.  
 
Level II 
discussion of cardiac 
related events 
specifically QT and 
sudden death, not 
excluded based on 
age, population, date 
of publication, or 
design type.  
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, gender, type of 
medication, dose of 
medication, duration 
of therapy. 
Dependent variables 
Heart rate, Blood 
pressure, ECG 
changes specifically 
QT prolongation and 
arrhythmia, sudden 
death.  
 
Amphetamines, 
Methylphenidate, 
and Amoxetine 
All were associated 
with small 
increases in HR (3-
6) bpm and 
elevation in 
systolic BP (2.1 
mmHG) of these, 
the majority of 
studies indicated 
the elevations were 
not statistically 
significant in 
children and 
adolescents. In the 
adult studies, the 
increased HR 
became statistically 
significant and 
remained so at 
endpoints up to 3 
years.  
 
No reports of 
QT/QTc 
prolongation in any 
studies.  
 
Arrhythmias 
 Arrhythmias were 
reported in 3 cases 
associated with use 
of 
Based on the 
comprehensive 
review of literature 
regarding 
cardiovascular side 
effects for ADHD 
medications it is 
evident that both 
stimulant and non-
stimulant 
medications cause 
marginal elevations 
in HR and BP. 
These effects are 
sometimes transient 
in children and tend 
to be more persistent 
in adults. Regardless 
of their incidence, 
the literature does 
not currently support 
a relationship 
between these 
increases in HR and 
BP and overall 
cardiovascular risk.  
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methylphenidate. 
One was 
immediately after 
IV administration, 
and one was after 
oral administration 
to a geriatric 
patient. The third 
case was in a 
healthy adolescent 
who used 
methylphenidate in 
conjunction with 
alcohol and 
nicotine. No 
arrhythmias were 
reported in the 
other drug classes. 
 
Sudden Death 
Of all the studies, 
incidences of 
sudden death were 
very rare and 
associated with 
concurrent use of 
other substances 
including alcohol, 
nicotine, and other 
stimulants. All of 
the studies 
concluded that 
ADHD 
medications are not 
associated with 
increased risk of 
sudden death, 
however patients 
should be screened 
for cardiovascular 
conditions prior to 
initiation of 
therapy.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Martinson, J., & Tang, H. (2010). 
Correlating family nurse 
practitioners' perspectives of 
adult ADD/ADHD with 
employed pharmacotherapy: a 
pilot study. Journal of The 
American Academy of Nurse 
Practitioners, 22(8), 424-430 
7p. doi:10.1111/j.1745-
7599.2010. 00527.x 
 
Purpose 
To determine how 
family nurse 
practitioners in the 
state of Washington 
view adult ADHD and 
how these views affect 
the pharmacotherapy 
they employ. 
Design 
Descriptive 
quantitative study; 
convenience 
sample 
 
Methods 
30 question survey 
mailed 
anonymously to 
126 participants. 
Convenience sample 
based on current 
FNP practice in the 
state of Washington 
in the area of acute 
and primary care for 
adults and family, 
geriatric health care, 
adult and women’s 
care, family and 
occupational health.  
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Responses 
analyzed using 
descriptive and 
Kendall’s rank 
correlations 
coefficient 
statistical methods. 
 
Level VI 
 
Of the 126 mailed, 
42 were returned 
completed response 
rate 41.6%, 
respondents were 
primarily female and 
Caucasian. Average 
practice length was 
6-10 years seeing an 
average of 40-79 
patients per week 
 Variables, 
Measurements 
Findings Future Implications 
 The questionnaire was 
developed to take 20-
30 minutes to 
complete and focuses 
on two dimensions 1) 
personal views od 
ADD/ADHD and the 
awareness that 
personal values may 
impact the treatment 
provided 2) preferred 
pharmacotherapy for 
ADD/ADHD and the 
comfort level in 
diagnosis, treating, as 
well as providing 
patient education and 
making referrals for 
ADD/ADHD.  
 
7 Items collected 
demographic data 
16 of the items were 
statement assessed 
using a 5 point Likert 
scale including agreed, 
disagreed, and 
undecided 
 
Short open-ended 
questions were also 
used to invite 
qualitative data  
Responses 
demonstrated a 
significant negative 
correlation between 
being comfortable 
diagnosing ADHD 
in adults and 
thinking it is 
important to refer 
to a specialist for 
treatment.  
There is a positive 
correlation between 
how respondent’s 
views determine 
the treatments they 
use and their 
comfort level 
treating adult 
ADHD in general 
Results 
demonstrated 
majority of 
providers did not 
view patients with 
ADHD as lazy or 
likely to abuse their 
ADHD 
medications 
(90.2%, 82.9% 
respectively) 
59% agreed adult 
ADHD is a 
disabling illness 
requiring treatment 
however 61% did 
not feel there was 
enough time for 
screening and 
diagnosis during a 
regular scheduled 
visit.  
Despite established 
adult ADHD 
treatment guidelines, 
the majority of 
providers in this 
study felt 
comfortable 
diagnosing, 
managing, and 
discussing ADHD 
with their adult 
patients.  
The results 
demonstrated that 
provider attitudes 
towards adults 
ADHD do influence 
prescribing 
practices. However, 
it appears provider 
attitudes support the 
need for 
pharmacological and 
primarily stimulant 
management of the 
condition. 
This small 
convenience sample 
gives insight to the 
phenomenon of 
adult ADHD 
management but 
larger case control 
studies would be 
required to 
demonstrate 
relationships among 
provider beliefs and 
prescribing 
practices. 
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In the qualitative 
portion, many 
providers indicated 
a preference to 
refer to specialist 
for diagnosis, and 
comfort in 
managing 
established 
medication 
regimens.  
66.7% prescribed 
stimulant therapy 
for adult ADHD 
 
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
McCarthy, S., Cranswick, N., Potts, L., 
Taylor, E., & Wong, I. K. 
(2009). Mortality associated 
with attention-deficit 
hyperactivity disorder (ADHD) 
drug treatment: a retrospective 
cohort study of children, 
adolescents and young adults 
using the general practice 
research database. Drug Safety, 
32(11), 1089-1096. 
doi:10.2165/11317630-
000000000- 
 Study aim 
To identify cases of 
sudden death in 
patients prescribed 
stimulant medications 
and Amoxetine to 
determine association 
between these and 
sudden death.  
A retrospective 
cohort study of 
children 
adolescents and 
adults taking 
medication for 
ADHD. 
 
Data was obtained 
from the UK 
General Practice 
Research Database 
via chart review 
and outcomes 
investigation using 
a questionnaire sent 
to PCPs.  
Patients were 
followed from date 
of first prescription 
to date of death, 
transfer out, age 
>21 years, or the 
end of the study.  
 
Level IV 
Patients identified 
from the database 
were aged 2-21 
years from January 
1, 1993 to June 30, 
2006 with a 
prescription for 
methylphenidate, 
dexamphetamine, or 
amoxetine.  
 
Of 18,637 patient 
years, 7 patients 
died. Cause of death 
was obtained for 6 
patients.  
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, sex, type of 
medication prescribed. 
Dependent variables 
Incidence of sudden 
death 
Cause of sudden death 
 
Sudden death 
according to the 
Of the 7 patients, 6 
causes of death 
were known; 
overdose of 
unknown intent, 
stab wounds, 
pancreatitis, 
suicide, suicide, 
brain tumor.  
 
This large 
population based 
study did not 
demonstrate any 
relationship among 
ADHD medications 
stimulant or non and 
an increased risk for 
sudden death. 
Based on the 
demonstrated rarity 
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WHO- instantaneous 
death and all deaths 
occurring within 24 
hours of an acute 
collapse, not including 
homicide, suicide, 
drowning, poisoning, 
or other unnatural 
causes.  
 
Standardized mortality 
ratios (SMR) were 
obtained using 
population data from 
the United Kingdom 
office for national 
statistics. 
The sample population 
was compared to the 
SMR using incident 
rate ratios.  
None of the deaths 
met criteria for 
sudden death. 
 
All 7 of the patients 
who died were 
taking stimulant 
medications.  
 
Incidentally, the 
incident rate of 
suicide was much 
higher in this 
cohort than the 
general population 
based on SMRs.  
 
of these events it 
may take a larger 
sample size to have 
the power to 
demonstrate the rate 
of occurrence.  
Incidental findings 
of higher risk of 
suicide among 
patients taking 
ADHD medications 
are a topic of current 
study and providers 
should be aware of 
these risks when 
treating this 
population.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Nelson, A., & Galon, P. (2012). 
Exploring the relationship 
among ADHD, stimulants, and 
substance abuse. Journal of 
Child & Adolescent Psychiatric 
Nursing, 25(3), 113-118 6p. 
doi:10.1111/j.1744-
6171.2012.00322.x 
 
Purpose 
To explore current 
state of prescription 
stimulant use for 
ADHD and the 
possible link to 
substance abuse.  
Current literature 
review accessed 
from PubMed 
database and 
cumulated index of 
nursing and allied 
health literature.  
Gather empirical 
data regarding the 
topic; identify what 
is known. 
 
Level V 
English language 
articles discussing 
ADHD, stimulant 
medications, and 
substance abuse.  
N= 34 articles 
 Variables, 
Measurements 
Findings Future Implications 
 Phenomenon of 
interest 
Gender, culture, 
ADHD as diagnosed 
by healthcare 
professional, age, 
socioeconomic status 
Outcomes 
Substance abuse 
 
Substance abuse- the 
inappropriate use of 
prescription or non-
prescription drugs, 
alcohol, or other 
agents 
 
Boys are 2.3 more 
likely to have 
ADHD than girls. 
Girls are more 
likely to present 
with inattentive 
type; boys are 
likely to present 
with hyperactive 
type.  
 
Cultural influences 
affect perceived 
severity of ADHD 
behaviors.  
 
Majority of ADHD 
assessments are 
The current 
literature 
demonstrates carried 
and conflicting 
reports regarding the 
risk of substance 
abuse in patients 
with ADHD. 
 
The majority of data 
indicate that early 
treatment of ADHD 
leads to more 
positive social 
functioning 
outcomes and may 
have a protective 
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DSM-IV definition of 
substance abuse- a 
maladaptive pattern of 
substance use leading 
to clinically significant 
impairment 
self-report 
measures with little 
consensus among 
providers. 
 
Current research 
demonstrates 
patients with 
known substance 
abuse disorder have 
a higher prevalence 
of ADHD 
compared to the 
general population 
 
The hallmark 
findings of 
impulsivity cannot 
be excluded as a 
predisposing 
character trait for 
substance abuse. 
 
No clear link 
between stimulant 
use and substance 
abuse has been 
made, independent 
of age of 
medication 
initiation. 
effect against 
substance abuse. 
 
ADHD occurs more 
frequently in the 
population of 
patients with known 
substance abuse 
disorders and should 
be a consideration 
for clinicians 
involved with these 
special populations. 
 
Further longitudinal 
controlled studies 
are needed to make 
delineate cause and 
effect relationships 
among ADHD 
diagnosis and 
substance abuse 
outcomes.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Pitts, M., Mangle, L., & Asherson, P. 
(2015). Impairments, diagnosis 
and treatments associated with 
attention-deficit/hyperactivity 
disorder (ADHD) in UK adults: 
Results from the lifetime 
impairment survey. Archives of 
Psychiatric Nursing, 29(1), 56-
63 8p. 
doi:10.1016/j.apnu.2014.10.001 
 
Purpose 
To assess the degree to 
which ADHD impairs 
patient’s everyday 
lives, and identify 
areas of life most 
impaired by this 
condition.  
Large online-based 
opinion survey. 
The survey was 
designed by 
psychiatrists and 
psychologists 
specializing in 
ADHD. Questions 
about impairment 
were combined into 
10 scales 
evaluating the level 
of difficulties 
currently 
encountered by 
patients with 
ADHD versus a 
control. 
Adults with and 
without ADHD 
were compared 
using t-tests for 
continuous data 
The sample 
population came 
from a voluntary 
consumer database 
for market research. 
Participants were 
identified by their 
answer to 
demographic 
questions including 
whether a doctor or 
healthcare 
professional has ever 
made a diagnosis of 
ADHD. 
A total of 210 
participants were 
included in the 
affected and control 
groups. (105 each). 
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and chi squared 
tests for categorical 
data. Mean 
impairment and 
symptom scores 
were calculated 
based on 
aforementioned 
scales.  
 
Level VI 
 Variables, 
Measurements 
Findings Future Implications 
 Independent variable 
Adult age, diagnosis 
of ADHD by a 
medical professional. 
Dependent variable 
ADHD impairment 
and symptom scores 
 
Impairment and 
symptom scale 
subjects 
 Mood/temper 
control 
 Work 
impairment 
 Self-
organization 
and planning 
 Involvement 
 Social 
impairment 
 Partnership 
impairment 
 Financial 
impairment 
 Rule-
breaking 
behavior 
 Perceived 
impact 
 Perceived 
impairment 
 
Based on the 
impairment and 
symptom scales 
there were 
significant 
differences among 
the ADHD and 
control groups in 7 
areas; 
mood/temper, work 
impairment, self-
organization. 
Social impairment, 
partnership 
impairment, 
financial 
impairment, and 
rule-breaking 
behavior 
(P<0.001). 
 
Demographic data 
demonstrated a 
broad range of co-
occurring 
conditions, 
especially sleep 
problems, and 
anxiety. 
 
1/3 of adults with 
ADHD received no 
treatment for their 
condition despite 
diagnosis by a 
medical 
professional.  
The individual items 
on each of the scales 
provide great insight 
into the specific 
obstacles faced by 
adults with ADHD. 
Long-term, patients 
with ADHD 
experience greater 
difficulty in all 
aspects of life 
including 
educational, work 
impairment, and 
social functioning.  
Despite 
demonstrated and 
reported 
impairments, not all 
patients received 
treatment for their 
condition. 
Only 25.8% reported 
treatment with 
medication. 
 
This study did not 
examine relationship 
between treatments 
and severity of 
impairments to 
determine 
therapeutic benefits. 
This study highlights 
the need for further 
larger population 
based studies to 
determine 
interventions which 
may augment 
patient’s perception 
of ADHD impact 
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and impairment over 
time.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Winters, K. C., Lee, S., Botzet, A., 
Fahnhorst, T., Realmuto, G. M., 
& August, G. J. (2011). A 
Prospective Examination of the 
Association of Stimulant 
Medication History and Drug 
Use Outcomes among 
Community Samples of ADHD 
Youths. Journal Of Child & 
Adolescent Substance Abuse, 
20(4), 314-329 16p. 
doi:10.1080/1067828X.2011.59
8834 
Purpose 
To describe the 
relationship of 
psychostimulant 
medication during 
childhood and 
subsequent substance 
use disorders and 
tobacco use.  
Longitudinal 
follow up study of 
an 
epidemiologically 
derived community 
based sample 
diagnoses with 
ADHD during 
childhood. DSM-
IV substance use 
criteria have been 
assessed at the 
three most recent 
data points.  
 
Data collected 
using in person and 
telephone 
interviews, 
collectors were not 
blind to ADHD 
status. 
Data was analyzed 
using the GEE 
method and was 
controlled for age 
and gender. 
 
Level III  
This sample was 
obtained from a 
larger ongoing study 
of youths identified 
to have disruptive 
behaviors before the 
age of 7. Patients in 
this sample have 
already been 
assessed at multiple 
data points at 11-15, 
and 12-16 years of 
age.  
ADHD sample 
N=149 and control 
N=93.  
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, age of diagnosis, 
diagnosis with DSM-
IV criteria for ADHD, 
externalizing versus 
non externalizing 
ADHD. 
Socioeconomic status, 
and medication history 
were accounted for. 
Dependent variables 
Prevalence of alcohol 
use disorder, 
prevalence of 
substance use disorder, 
prevalence of nicotine 
use 
 
Socioeconomic status 
determined using four 
Difference in 
frequency of 
substance use was 
only statistically 
significant at T4 
for marijuana use 
among ADHD 
participants.  
 
There was no 
difference in 
outcomes among 
the three different 
medication groups. 
 
The overall 
incidence of 
substance abuse 
and nicotine use is 
higher in the 
ADHD population 
This study did not 
randomize its 
subjects to be able to 
determine 
experimentally if 
medication for 
ADHD with controls 
for age may actually 
decrease rates of 
substance abuse. 
 
The study does 
negate the 
previously published 
notion that stimulant 
medications increase 
the rate of substance 
abuse later in life.  
 
Further experimental 
studies would be 
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factor index of social 
status based on 
parental reporting 
ranged from unskilled 
to major 
business/professional. 
 
Medication history 
was determined by 
simple reporting of 
psychostimulant 
medication use 1) 
never used, 2) 
medication prescribed 
and used up to age 12, 
but no later, 3) 
medication prescribed 
and used after age 12 
including childhood 
and later 
 
Substance use was 
measured using DSM-
IV criteria for 
substance use 
disorders module of 
structured interviews. 
than in the normal 
control group. 
 
There is no 
evidence to suggest 
that ADHD 
medication at any 
time period 
increases risks of 
substance abuse 
later in life.  
needed to determine 
how ADHD 
medications may be 
beneficial in 
reducing the lifetime 
instance of 
substance abuse in 
this population.  
Author, Date Topic, Purpose, Study 
Questions 
Method, Study 
Design 
Sample, Population 
Winterstein, A. G., Gerhard, T., Kubilis, 
P., Saidi, A., Linden, S., Crystal, 
S., & ... Olfson, M. (2012). 
Cardiovascular safety of central 
nervous system stimulants in 
children and adolescents: 
population based cohort study. 
BMJ: British Medical Journal 
(Clinical Research Edition), 
345e4627-e4627 1p. 
doi:10.1136/bmj.e4627 
Objectives 
To evaluate cardiac 
safety of central 
nervous system 
stimulants in children 
and adolescents. 
Population based 
retrospective 
cohort study 
Utilized automatic 
claims data for 
Medicaid 
participants from 
years 1999-2006. 
Data included 
inpatient and 
outpatient services 
as well as 
medications 
reimbursed by 
Medicaid. Death 
records were 
obtained from 
social security 
master death file 
and the national 
death index.  
 
Data were analyzed 
using time survival 
analysis framework 
to compare data 
endpoints 
Sample assembled 
of children and 
young people (age 
3-18) from 28 
Medicaid programs 
with a diagnosis of 
ADHD separated 
into two groups 
based on stimulant 
use or non.  
Exclusion criteria: 
transplant recipient, 
receipt of dialysis, 
substance abuse.  
Risk categories were 
stratified by flagging 
of high risk disease 
states such as 
congenital heart 
disease, malignant 
neoplasms etc.  
N=1,219,847 
children 
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occurring during 
stimulant use 
versus non, Hazard 
ratios were also 
applied. 
 Variables, 
Measurements 
Findings Future Implications 
 Independent 
variables 
Age, stimulant use, 
presence of another 
high risk health 
condition, sex, race, 
state of residence, 
reason for eligibility 
for Medicaid 
 
Dependent variables 
Primary endpoints; 
cardiovascular risk as 
defined by sudden 
cardiac death, acute 
myocardial infarction, 
and stroke. Secondary 
endpoint; hospital 
admission for 
ventricular arrhythmia 
was added to capture 
negative chronotropic 
effects. 
 
Logistic regression 
was used to calculate 
propensity scores to 
estimate the likelihood 
of receiving 
stimulants. Separate 
regression models 
were used for each 
cohort group. 
Pearson’s x2 was used 
to test proportion of 
covariates.  
In the affected 
population, young 
children Caucasian 
males were 
overrepresented. 
This is consistent 
with other 
literature. 
 
Average duration 
of stimulant 
treatment was 1.2-
0.6 months. 
 
There were 66 
cases of sudden 
cardiac death, 
stroke, or acute MI. 
Event rate 2.8 per 
100,000 patient 
years.  
Broken down by 
cohort group 
3.5/100,000 for 
non-users 
1.7/100,000 for 
current users 
1.5/100,000 for 
former users 
 
26 events occurred 
in high risk patients 
63/100,000 patient 
years 
Stimulant use did 
not increase 
cardiovascular risk 
in this population 
 
Inclusion of the 
second endpoint; 
ventricular 
arrhythmia 
increased events to 
95, but had similar 
offs ratios at the 
composite endpoint 
after censoring for 
This was a large 
study representing 
more than a quarter 
of all US children. 
Similar to other 
smaller studies, 
despite a large 
sample size there 
were very few 
events.  
This study did not 
exclude high risk 
populations and 
accounted for them 
by stratifying the 
data points.  
 
None of the 
endpoints suggested 
any increased 
cardiovascular risk 
for patients taking 
stimulant medication 
for ADHD. 
 
Further research is 
needed to determine 
cardiovascular risk 
over time with long-
term stimulant use.  
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trauma and acute 
infection.  
 
